Today at 6:07 AM ET, Gilead Sciences stock fell 1.4% to $76.70 in the pre-market session. According to reports, remdesivir failed its first clinical trial.
Johnson & Johnson stock rose 4.7% as of 12:30 PM ET today. Investors are optimistic about the company’s strong first-quarter results and a dividend hike.
Johnson & Johnson (NYSE:JNJ) stock rose immediately after the company announced that an experimental coronavirus vaccine might be available by September.
In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.
Renaissance Technologies had a strong investment in the healthcare sector in Q2 2019. The healthcare sector makes up 18.16% of the firm’s total portfolio.
According to the CDC, about 400,000 people died from opioid overdoses from 1999 to 2017. The number includes deaths from prescription and illegal opioids.
Johnson & Johnson has a much broader revenue base than Teva. The company also has a solid presence in the medical devices and consumer healthcare areas.
According to Johnson & Johnson’s first-quarter earnings conference call, Erleada gained a four-percentage-point market share in the US on a YoY basis. The drug is now being prescribed equally by urologists and well as oncologists, the two key prescribers for prostate cancer drugs.
Johnson & Johnson’s (JNJ) Pharmaceutical segment is the company’s key revenue driver and accounted for 51.17% of the company’s total revenues in the first quarter. Darzalex, Stelara, Tremfya, and Imbruvica reported double-digit YoY revenue growth in the first quarter.
In its first-quarter earnings press release, Johnson & Johnson (JNJ) has increased its fiscal 2019 adjusted diluted operational EPS guidance from the previously projected $8.65 to $8.80, which implies YoY growth of 5.7%–7.6%, to $8.73–$8.83, which implies a YoY rise of 6.7%–7.9%. The company also increased the lower end and narrowed its fiscal 2019 adjusted diluted EPS guidance from $8.50–$8.65.
In its first-quarter earnings conference call, Johnson & Johnson (JNJ) forecasted a stronger operational revenue growth outlook and expects YoY adjusted operational sales growth of 2.5% to 3.5% and operational sales growth of 0.5% to 1.5% for fiscal 2019. The company has also guided for a YoY reported sales decline of 1.5% to 0.5% for fiscal 2019 based on the euro spot rate of $1.12.
Johnson & Johnson (JNJ) is up by 10.10%, and Gilead Sciences (GILD) is up by 10.92% on a YTD basis. Both the companies are struggling due to intense competitive pressures either from branded or generic competitors. The consensus recommendation for both Johnson & Johnson and Gilead Sciences is a “buy.”
Twitter (TWTR) recently rolled out new reporting tools for its users in India, allowing them to more easily flag misinformation about voting in the country.
In the first quarter, Johnson & Johnson’s (JNJ) Pharmaceutical segment reported 7.9% YoY (year-over-year) growth in worldwide revenue on an operational basis.
In the first quarter, Johnson & Johnson’s (JNJ) Consumer segment reported 2.2% YoY (year-over-year) growth in worldwide revenues on an operational basis.
Legacy immunology drugs In the first quarter, Johnson & Johnson (JNJ) reported Remicade sales worth $1.10 billion, a YoY (year-over-year) decline of 20.6% on a reported basis and 19.1% on an operational basis. According to Johnson & Johnson’s first quarter earnings conference call, despite maintaining volume share of 92% in the infliximab market, Remicade sales […]
Immunology revenue performance In the first quarter, Johnson & Johnson (JNJ) reported immunology sales of $3.25 billion, a YoY (year-over-year) rise of 6.9% on a reported basis and 9.6% on an operational basis. The company reported immunology sales worth $2.16 billion in the U.S. market, a YoY rise of 8.1% on a reported and operational basis. […]
Revenue guidance for fiscal 2019 In its first-quarter earnings press release, Johnson & Johnson (JNJ) has raised the guidance for its adjusted operational sales growth rate for fiscal 2019 from previously projected 2.0% – 3.0% to 2.5% – 3.5%. The company has also raised its fiscal 2019 operational sales guidance from $81.6 billion – $82.4 […]
In its fourth-quarter earnings investor presentation, Johnson & Johnson (JNJ) highlighted increasing biosimilar and generic competition, pricing pressure, and the strengthening of the US dollar as key challenges for the company in fiscal 2019.
In its fourth-quarter earnings investor presentation, Johnson & Johnson (JNJ) has projected its effective tax rate for fiscal 2019 to fall in the range of 17% to 18%.
In its fourth-quarter earnings investor presentation, Johnson & Johnson (JNJ) projected its operational sales to fall in the range of $81.6 billion to $82.4 billion in fiscal 2019.
In its third-quarter earnings conference call, Johnson & Johnson (JNJ) highlighted its strategy of creating value for shareholders by entering collaborations and external partnerships.
Wall Street analysts have forecasted Johnson & Johnson’s gross margins to be 71.09%, 71.18%, and 71.30%, for fiscal 2018, fiscal 2019, and fiscal 2020, respectively.
In its third-quarter earnings conference call, Johnson & Johnson (JNJ) has forecasted its fiscal 2018 adjusted EPS to fall in the range of $8.13–$8.18.
In its third-quarter earnings press release, Johnson & Johnson (JNJ) has forecasted its revenues for fiscal 2018 to be in the range of $81.0 billion to $81.4 billion.
In fiscal 2018 and fiscal 2019, Thermo Fisher Scientific (TMO) is expected to generate revenue of $24.08 billion and $25.19 billion, respectively, compared with revenue of $20.92 billion in fiscal 2017.
In fiscal 2018 and fiscal 2019, Abbott Laboratories (ABT) is expected to generate revenue of $30.66 billion and $32.21 billion, respectively, compared with revenue of $27.39 billion in fiscal 2017.
In its third-quarter earnings conference call, Tesaro (TSRO) narrowed its revenue guidance for fiscal 2018 from the previously projected range of $250 million to $265 million to $258 million to $265 million.
Of the 26 analysts covering Regeneron Pharmaceuticals (REGN), eight recommend “buy” or a higher rating, 17 recommend “hold,” and one recommends “sell.”
In fiscal 2018 and fiscal 2019, Regeneron Pharmaceuticals (REGN) is expected to generate revenue of $6.49 billion and $7.16 billion, respectively, compared with revenue of $5.87 billion in fiscal 2017.
In December 2018, of the total 16 analysts covering Endo International (ENDP), five analysts have given Endo stock a “buy” or higher rating and 11 analysts have given it a “hold” rating.
In November 2018, of the total 29 analysts covering Stryker (SYK), 19 analysts gave Stryker stock a “buy” or higher rating, and ten analysts have given it a “hold” rating.
This month, of the total ten analysts covering Tandem Diabetes Care (TNDM), seven have given the stock a “buy” or higher rating and three have given it a “hold” rating.
Tandem Diabetes Care’s (TNDM) key focus is its t:slim X2 insulin delivery system, which is designed to display continuous glucose monitoring directly on a pump’s home screen.
In November 2018, of the total 18 analysts covering Alexion Pharmaceuticals (ALXN), 16 analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating.
JNJ’s Interventional Solutions segment generated third-quarter net revenues of $653.0 million, compared to $553.0 million in the third quarter of 2017.
In the US and international markets, Johnson & Johnson’s Diabetes Care segment generated third-quarter net revenues of $125.0 million and $190.0 million, respectively.
Johnson & Johnson’s (JNJ) beauty business generated revenue of $1.1 billion in the third quarter compared to $1.0 billion in the third quarter of 2017.
